KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Eli Lilly (LLY) Equity Average (2016 - 2025)

Historic Equity Average for Eli Lilly (LLY) over the last 17 years, with Q4 2025 value amounting to $25.2 billion.

  • Eli Lilly's Equity Average rose 7621.91% to $25.2 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $25.2 billion, marking a year-over-year increase of 7621.91%. This contributed to the annual value of $20.4 billion for FY2025, which is 6234.68% up from last year.
  • As of Q4 2025, Eli Lilly's Equity Average stood at $25.2 billion, which was up 7621.91% from $21.1 billion recorded in Q3 2025.
  • In the past 5 years, Eli Lilly's Equity Average ranged from a high of $25.2 billion in Q4 2025 and a low of $6.5 billion during Q1 2021
  • Its 5-year average for Equity Average is $12.2 billion, with a median of $11.2 billion in 2023.
  • In the last 5 years, Eli Lilly's Equity Average surged by 11919.68% in 2021 and then surged by 587.26% in 2023.
  • Eli Lilly's Equity Average (Quarter) stood at $8.6 billion in 2021, then increased by 22.4% to $10.5 billion in 2022, then rose by 5.87% to $11.1 billion in 2023, then grew by 28.96% to $14.3 billion in 2024, then skyrocketed by 76.22% to $25.2 billion in 2025.
  • Its Equity Average was $25.2 billion in Q4 2025, compared to $21.1 billion in Q3 2025 and $17.1 billion in Q2 2025.